Children who develop viral infection, including rhinovirus and respiratory syncytial virus, are at increased risk of developing subsequent acute respiratory infection, as shown in a recent study from the Philippines.
Tuberculosis (TB) is an important adverse event associated with the use of biologics, especially antitumour necrosis factor, in the management of autoimmune inflammatory rheumatic diseases, according to a study. Prophylaxis can effectively reduce the risk in patients testing positive for latent TB at screening.
Initial treatment with intravenous immunoglobulin (IVIG) plus infliximab lessens the need for additional therapy in Kawasaki disease (KD) patients presenting with coronary artery lesions (CALs), a recent study has shown.
It is safe to revaccinate patients with a history of mild or moderate adverse events following immunization (AEFI), but more research is required in those with serious AEFIs who are less likely to be reimmunized, suggests a recent study.
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.